Glioblastoma multiforme therapy and mechanisms of resistance. - Wikidata - awgldk - TriplyDB

Glioblastoma multiforme therapy and mechanisms of resistance.

Glioblastoma multiforme therapy and mechanisms of resistance.

http://www.wikidata.org/entity/Q37415954

about

Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.The medicinal chemistry of imidazotetrazine prodrugs Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine Engineering a High-Throughput 3-D In Vitro Glioblastoma Model.Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.Recent advances and future of immunotherapy for glioblastoma.The mechanisms of malic enzyme 2 in the tumorigenesis of human gliomas.The nanomaterial toolkit for neuroengineering.CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.Drug delivery approaches for the treatment of glioblastoma multiforme.Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion.Glioma Cell Invasion is Significantly Enhanced in Composite Hydrogel Matrices Composed of Chondroitin 4- and 4,6-Sulfated Glycosaminoglycans IL13RA2 targeted alpha particle therapy against glioblastomas.Properties and reactivity of nucleic acids relevant to epigenomics, transcriptomics, and therapeutics.Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.The taxonomy of brain cancer stem cells: what's in a name?The Process and Regulatory Components of Inflammation in Brain Oncogenesis.Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma.Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker.Inhibition of HIF1α and PDK Induces Cell Death of Glioblastoma Multiforme.A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival.Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.Solid Lipid Curcumin Particles Induce More DNA Fragmentation and Cell Death in Cultured Human Glioblastoma Cells than Does Natural Curcumin.Use of nanoparticles for glioblastoma treatment: a new approach.Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.Design and synthesis of a MAO-B-selectively activated prodrug based on MPTP: a mitochondria-targeting chemotherapeutic agent for treatment of human malignant gliomas.Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.Pro-apoptotic and anti-angiogenic properties of the α /β-thujone fraction from Thuja occidentalis on glioblastoma cells.Impact of PKCε downregulation on autophagy in glioblastoma cells.Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway.Monocyte-mediated chemotherapy drug delivery in glioblastoma.Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.

P2860

Q33627880-0B80E4D3-75DE-45AB-8780-DF70690054D8 Q33963114-CEB15EDA-EAB6-46AA-B1E8-F24F346BAA3E Q34276149-30C46AD9-3D7E-4785-BC9E-DEDBFA0840E6 Q35657822-CB027380-E2AB-412D-8FB5-8227E73D9622 Q36145632-C4F49D9B-75A3-419C-8B0F-D246C44FB505 Q36403289-3A200720-FCAD-47AE-A569-23F4B8E327A0 Q36844539-2032056E-2DD6-4087-B336-51ECBA72D12F Q37232935-E4B82F69-D4BD-414B-A005-DA59C990CC2B Q37239071-068F27E9-C33F-418D-91CE-53499227939D Q37520257-E5408F27-5067-450D-89D5-88690266A96F Q37610362-586BA0A9-BC94-451A-A4C1-67778E4ADAE0 Q37686164-4C664D36-D071-4EF7-BB55-2DDA3F505F02 Q38517047-75FD8595-4618-4A2F-BFA6-5770E0ADEAC0 Q38697415-6486B25A-34C5-4453-BADF-050D27B1B2F1 Q38715700-B60FF2DD-D375-413F-9FC8-68B57898608D Q38754116-275B3A34-A24F-4C84-8F18-630A66D11A8A Q38780402-5CA2E715-3025-4A60-9B90-C01C19BD44E3 Q38813588-EF108744-08DA-457C-BC6E-4824AB78E299 Q38944343-A2E4182B-59AB-46C2-82ED-0DC93A000798 Q38998571-876C3C5E-ACF3-46BE-86AE-6F96BF3F8497 Q39056846-3BFCB89D-2421-4BF5-A430-62B0F0C1D26C Q39202332-D5AD2054-D24D-43D3-9CA4-587C2F4DBBCB Q41098467-92B6F56C-D2C2-469E-9CD3-821D5367EE28 Q41484629-E8D6D288-1001-4C32-BE59-11B14FCB39A4 Q41612568-1C464365-D766-432A-B4CE-7F5082F9E685 Q43725271-008213DB-C55F-4ECC-A049-745F74DC92B5 Q45966683-3D782481-B519-4503-BA6F-C8F65385B55F Q46563593-70CBDD83-60F6-469D-835D-591AFE656623 Q47845944-1A9AFD4C-243D-4F6A-8E34-613E54E640A2 Q48095060-9F599459-868A-45DE-A9A4-96CC309282D1 Q48128887-99F06E63-15B5-4BCE-B3AC-4746512E47A7 Q48181924-F64C2A6A-B2C5-4EB1-952D-5935E00FC210 Q48331700-7DE40863-F9EA-4436-B8F7-BFABB90E4C03 Q48444978-A7669189-FCA3-441A-B3C0-C142FFC04495 Q48888906-BBE6F80D-5FDC-40FE-AE6E-444EEF0C446E Q49190512-2F48918D-475B-4CD3-AC19-8E494BC42660 Q49533311-6274BCDA-B824-46E7-82CC-EB032AF7C4D2 Q49664694-121EC005-2404-467F-A022-4BC7E3DABEFB Q50582458-6CD0350C-3131-4A55-9A8F-2E82F8A88EE1 Q52590668-209EAFFE-EC38-4AD7-90E6-004C1CEE5124

P2860

Glioblastoma multiforme therapy and mechanisms of resistance.

http://www.wikidata.org/entity/Q37415954

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Glioblastoma multiforme therapy and mechanisms of resistance.

@en

Glioblastoma multiforme therapy and mechanisms of resistance.

@nl

type

label

Glioblastoma multiforme therapy and mechanisms of resistance.

@en

Glioblastoma multiforme therapy and mechanisms of resistance.

@nl

prefLabel

Glioblastoma multiforme therapy and mechanisms of resistance.

@en

Glioblastoma multiforme therapy and mechanisms of resistance.

@nl

P1433

Q37415954-B1B4F8D2-9417-4674-8EA7-B708AD7CBC91

P1476

Q37415954-9D9A3AE4-7044-4FCC-8897-104F4EAC6E41

P2093

Q37415954-66CDD50A-6FC3-4080-BD07-EE176643E1DE

Q37415954-9130E5B5-3253-48BC-977C-FA28B233D536

Q37415954-C929F35D-AD92-41E4-9C19-9E41C12E386D

P2860

Q37415954-0070A7FE-02DA-4F9B-B6CD-D201C093F07F

Q37415954-0086FDD3-B8E9-4DCC-BACC-B887CF81B414

Q37415954-0140D07C-44BB-4A59-8EDB-F3D08F0C3994

Q37415954-02A05A8C-0AE1-40EB-92AB-4E71543D9BB5

Q37415954-05285D20-8648-4FE1-B57B-E48A6D330D08

Q37415954-07F6F2EB-8D32-46A9-AC8F-4FB608965A9E

Q37415954-0CB67C3A-E816-405F-93EB-E188C5893978

Q37415954-0D053D96-36B9-4E94-87E9-303002474E9A

Q37415954-0F1E2F94-2005-40C9-B59B-5EFA034BEF06

Q37415954-198D3C26-0088-4788-B13B-EF83AE637C45

P304

Q37415954-A72429C2-8713-4096-9C6C-6DF0DD3406CE

P31

Q37415954-AF86E7D5-3E2B-465B-B155-A21B179F6696

P356

Q37415954-78D05256-32E6-47D7-82DA-25EC141180F3

P433

Q37415954-538B6EE6-DF91-4BCB-9CE9-607263B796E7

P478

Q37415954-3C60C612-8129-4956-B861-BF632CA518C2

P50

Q37415954-E8A4E23B-C51F-4ED2-B65A-A6BB8D4AECAF

P577

Q37415954-3DCA78D0-6937-447E-8C04-06A0EB0F18D2

P5875

Q37415954-DBD0B056-8153-4129-89EA-9AA155434EC7

P698

Q37415954-ADFE360C-52C6-4EEC-B8A6-C24806024A0A

P932

Q37415954-BC96C703-6DEB-486B-AD59-73A1D153575E

P356

P1433

Pharmaceuticals

P1476

Glioblastoma multiforme therapy and mechanisms of resistance

@en

P2093

Alonzo H Ross

http://www.w3.org/2001/XMLSchema#string

Jessica L Weatherbee

http://www.w3.org/2001/XMLSchema#string

Yulian P Ramirez

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Akt and autophagy cooperate to promote survival of drug-resistant glioma

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

An integrated genomic analysis of human glioblastoma multiforme

Neural stem cells: involvement in adult neurogenesis and CNS repair

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

P304

1475-1506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH6121475

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Richard T. Wheelhouse

P577

2013-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259003032

http://www.w3.org/2001/XMLSchema#string

P698

24287492

http://www.w3.org/2001/XMLSchema#string

P932

3873674

http://www.w3.org/2001/XMLSchema#string